On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
June 02 2022 - 7:00AM
Business Wire
Report lays out blueprint for achieving
Organon’s purpose and business imperatives to help women and girls
achieve their promise through better health
- Launch of Her Promise ESG platform creates a framework by which
Organon aims to advance innovation and progress in women’s health
and contribute to UN Sustainable Development Goals
- Through the Her Promise Access Initiative, Organon’s goal is to
provide 100 million girls and women in low- and middle-income
countries with affordable access to contraceptive options by
2030
- Funding to global NGO Women Deliver for their Young Leaders
Program and other advocacy work, including support for young people
around the world to advocate for and advance women’s health and
gender equality
Organon (NYSE: OGN), a global women’s healthcare company, today
announced the publication of its inaugural Environmental, Social,
and Governance (ESG) Report for 2021. The ESG Report introduces
Organon’s ESG platform, known as Her Promise, and details how the
company is working to help women and girls achieve the full
potential of their promise through better health. The publication
of the ESG Report and launch of Her Promise coincides with
Organon’s one year anniversary and reflects the company’s vision to
create a better and healthier every day for every woman around the
world.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220602005205/en/
Organon Her Promise Mural found at
Organon global headquarters in Jersey City, New Jersey. Created by
local Japanese American artist Riiisa Boogie who crafts detailed
imaginary through textile, nature, portraits, flowing abstractions
and uniquely creative characters. (Photo: Organon)
As the only global women’s health company of its kind, Organon
is well positioned to help address several current and growing
women’s health challenges. For example, nearly half of all
pregnancies worldwide – about 121 million in total – are
unintended. According to a 2019 study, an estimated 218 million
women and girls (ages 15-49) in low-and-middle income countries had
an unmet need for modern contraception. Through Her Promise,
Organon is making focused investments and forming strategic
partnerships with the goal of introducing and expanding access to
health solutions that improve women’s health and advance gender
equity, inside and outside Organon.
“In just one year, Organon has made considerable progress in
addressing gender-related disparities in health by listening to
women and investing in areas where high unmet needs exist. Since
our launch, we have focused on treatment gaps that need to be
addressed, like unintended pregnancy, fertility, post-partum
hemorrhage, pre-term labor, endometriosis, and bacterial vaginosis,
and will continue to strive to deliver innovation, improve access
and expand choice for women,” says Kevin Ali, Organon’s Chief
Executive Officer. “The goals stated in our first ESG Report create
a roadmap for the future of how we will continue to propel forward
and partner to transform the current women’s health
environment.”
On its one-year anniversary, Organon is making the following
goals to achieve Her Promise:
- To improve access to low-cost contraceptive options in 69 of
the world’s least developed countries. Through the
Organon Her Promise Access Initiative, Organon is
working with global organizations to provide family planning
information, education and access to low-cost contraceptive
options. Organon’s goal is to provide 100 million girls and women
in low- and middle- income countries with affordable access to
contraceptive options by 2030.
- To redefine and harness innovation in women’s health.
Organon will dedicate a majority of its pre-clinical and clinical
development activity toward the unmet health needs of women.
Organon has already begun with development activities in high unmet
need areas including postpartum hemorrhage, endometriosis, and
pre-term labor.
- Expand access to treatment options that improve her health
and help secure her promise. Working together with global
organizations, Organon plans to expand access to treatment options
for post-partum hemorrhage in women, in both developed and
developing markets. We will also seek to help address affordability
of fertility treatments and access to education to decrease the
unmet medical need in fertility.
- Aim to achieve balanced gender representation through all
levels of Organon globally by 2030 and pay equity. Organon has
had a strong start by launching with a Board of Directors that
consists of accomplished individuals with exceptional skills and
expertise, and also represents gender and racial diversity.
Currently, Organon’s Board is the most diverse healthcare board on
the S&P 500.
- Aim to support the transition to a low carbon economy, with
an ambition to achieve net zero greenhouse gas emissions. We
also aim to integrate water stewardship and circular economy
principles into our business models. The report details concrete
short- and mid-term actions we will take to meet these long-term
ambitions.
- Uphold the highest levels of ethics and integrity throughout
its business.
In addition, as part of its commitment to advancing gender
equity through Her Promise, Organon has provided US $1.4M to Women
Deliver to fund its Young Leaders Program and other advocacy work,
as well as support the Women Deliver 2023 Conference (WD2023). The
funding will help Young Leaders across the world to achieve their
advocacy goals in gender equality and health through financial
resources, mentorship, and technical assistance.
“The Board is committed to achieving both Organon’s business
goals as well as contributing to societal goals, and to continuing
to drive the company’s ESG strategy,” says Carrie Cox, Board
Chairman. “We are pleased to be in a position to publish a
comprehensive ESG report just one year after the company’s
establishment as a standalone company and highlight our purpose and
goals in improving the health of women and girls.”
The Board’s governance committee, called the ESG Committee, is
comprised of five members and chaired by pharmaceutical industry
veteran Robert Essner, all of whom bring considerable expertise
from across a variety of disciplines.
For more details on Organon’s ESG strategy, priorities, and
initiatives, download the full 2021 ESG Report at
https://www.organon.com/about-organon/environmental-social-governance/.
About Organon Organon is a global healthcare company with
a focus on improving the health of women throughout their lives.
Organon has a portfolio of more than 60 medicines and products
across a range of therapeutic areas. Led by the women’s health
portfolio coupled with an expanding biosimilars business and stable
franchise of established medicines, Organon’s products produce
strong cash flows that will support investments in innovation and
future growth opportunities in women’s health. In addition, Organon
is pursuing opportunities to collaborate with biopharmaceutical
innovators looking to commercialize their products by leveraging
its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and
geographic reach, world-class commercial capabilities, and
approximately 9,300 employees with headquarters located in Jersey
City, New Jersey.
For more information, visit http://www.organon.com and
connect with us on LinkedIn and Instagram.
Forward-Looking Statement of Organon Organon makes
various statements in this press release, including, but not
limited to, statements about management’s expectations about
Organon’s environmental, social, and governance strategy and goals.
These “forward-looking statements” may be identified by words such
as “expects,” “intends,” “anticipates,” “plans,” “believes,”
“seeks,” “estimates,” “will” or words of similar meaning. These
statements are based upon the current beliefs and expectations of
the company’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks
or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Organon
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements
can be found in Organon’s filings with the Securities and Exchange
Commission ("SEC"), including the company’s Annual Report on Form
10-K for the year ended December 31, 2021 and subsequent SEC
filings, available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220602005205/en/
Media:
Karissa Peer (614) 314-8094
Kate Vossen (732) 675-8448
Investors:
Jennifer Halchak (201) 275-2711
Edward Barger (267) 614-4669
Organon (NYSE:OGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Organon (NYSE:OGN)
Historical Stock Chart
From Sep 2023 to Sep 2024